Exagen Inc Stock Net Income

XGN Stock  USD 1.40  0.01  0.72%   
Exagen Inc fundamentals help investors to digest information that contributes to Exagen's financial success or failures. It also enables traders to predict the movement of Exagen Stock. The fundamental analysis module provides a way to measure Exagen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Exagen stock.
Last ReportedProjected for Next Year
Net Loss-23.7 M-24.9 M
Net Loss-42.6 M-40.5 M
Net Loss-32.5 M-34.1 M
Net Loss(1.34)(1.41)
Net Income Per E B T 1.00  1.10 
As of the 4th of May 2024, Net Income Per E B T is likely to grow to 1.10, while Net Loss is likely to drop (24.9 M).
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Exagen Inc Company Net Income Analysis

Exagen's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current Exagen Net Income

    
  (23.69 M)  
Most of Exagen's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Exagen Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Exagen Net Income Driver Correlations

Understanding the fundamental principles of building solid financial models for Exagen is extremely important. It helps to project a fair market value of Exagen Stock properly, considering its historical fundamentals such as Net Income. Since Exagen's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Exagen's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Exagen's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Exagen Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

(75.51 Million)

Exagen reported last year Accumulated Other Comprehensive Income of (79.48 Million)
Based on the recorded statements, Exagen Inc reported net income of (23.69 Million). This is 106.94% lower than that of the Biotechnology sector and 113.68% lower than that of the Health Care industry. The net income for all United States stocks is 104.15% higher than that of the company.

Exagen Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Exagen's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Exagen could also be used in its relative valuation, which is a method of valuing Exagen by comparing valuation metrics of similar companies.
Exagen is currently under evaluation in net income category among related companies.

Exagen Institutional Holders

Institutional Holdings refers to the ownership stake in Exagen that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Exagen's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Exagen's value.
Shares
Ubs Group Ag2023-12-31
62.4 K
Blackrock Inc2023-12-31
57.8 K
Renaissance Technologies Corp2023-12-31
45.5 K
Bridgeway Capital Management, Llc2023-12-31
40.8 K
Dimensional Fund Advisors, Inc.2023-12-31
36 K
State Street Corporation2023-12-31
33.7 K
Millennium Management Llc2023-12-31
23.6 K
Northern Trust Corp2023-12-31
16.4 K
First Bank & Trust (brookings Sd)2023-12-31
13.5 K
Rtw Investments, Llc2023-12-31
1.5 M
Cowen And Company, Llc2023-12-31
898.6 K

Exagen Fundamentals

About Exagen Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Exagen Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Exagen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Exagen Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock:
Check out Exagen Piotroski F Score and Exagen Altman Z Score analysis.
Note that the Exagen Inc information on this page should be used as a complementary analysis to other Exagen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Exagen Stock analysis

When running Exagen's price analysis, check to measure Exagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Exagen is operating at the current time. Most of Exagen's value examination focuses on studying past and present price action to predict the probability of Exagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Exagen's price. Additionally, you may evaluate how the addition of Exagen to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Global Correlations
Find global opportunities by holding instruments from different markets
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Is Exagen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.34)
Revenue Per Share
2.972
Quarterly Revenue Growth
0.072
Return On Assets
(0.20)
Return On Equity
(0.73)
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.